**Market Brief: Healthcare Sector & Union Budget 2026** **Sector Sentiment: Bullish** Indian healthcare stocks witnessed a sharp upside momentum today following the Union Budget 2026-27 presentation. The headline announcement of a **Rs 10,000 crore** "Biopharma Shakti" initiative has catalyzed buying interest across large-cap and mid-cap pharma counters. **Key Budget Announcements** Finance Minister Nirmala Sitharaman unveiled a strategic roadmap to position India as a global healthcare destination. The central government will partner with states and the private sector to establish **five Regional Medical Hubs**. These integrated complexes are designed to streamline medical value tourism, offering end-to-end services for international patients. To support this infrastructure, the Centre targets training **1.5 lakh caregivers** and allied health professionals. This workforce expansion aims to bridge the domestic skill gap while meeting the rising demand for geriatric and specialized care services globally. **Biopharma Shakti Initiative** The most significant trigger for the sector is the **Rs 10,000 crore** outlay for the "Biopharma Shakti" scheme over the next five years. This capital is allocated to accelerate the domestic production of complex biologics and biosimilars, moving the industry up the value chain from traditional generics. The initiative includes upgrading seven existing National Institutes of Pharmaceutical Education and Research (NIPERs) and establishing **three new NIPERs** focused specifically on biopharma R&D. **Market Reaction & Trends** The Nifty Pharma index, which had been consolidating around the **21,500** level leading up to the budget, broke out on strong volume. Market participants are pricing in improved margins for companies with robust biosimilar pipelines, viewing the subsidy and infrastructure support as a direct earnings booster. Analysts project the Indian medical tourism market to surpass **$13 billion** by the end of 2026, driven by the new visa easing norms and the dedicated regional hubs. The focus on high-value "Heal in India" programs is expected to benefit hospital chains with significant metro presence. **Strategic Outlook** Investors are closely watching the implementation of the **1,000+ accredited clinical trial sites** network also proposed in the budget. This move is anticipated to slash drug approval timelines, potentially attracting higher foreign direct investment (FDI) into contract research organizations (CROs) and domestic drug makers. *